Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shareholder's meeting next month fwiw. Basically voting for approval for a reverse split in the range of 8 to 25 shares. Also of note we're now up to just under 20 million shares outstanding with the dilution from the convertible note.
I haven't. I would be hesitant to say.
Wow. I've never been in this one but that really is potentially about as bad as it gets I would think
Takes at least six months and appeals. I'm guessing they'll appeal with a reverse split plan
Yeah it's hard to wait them out. Looks like 12-15 months
Let's hope
I'm more interested in the mushroom compounds in regards to synaptic effects but not a lot of detail in that PR
Not really sure what it means for us or how it plays out but the company did acquire a stake in an Israeli research lab or something similar today. Doesn't appear to be anything synergistic with Bryostatin but the diversification is probably the point...that and trying to see previous lenders get some of their money back in some fashion that is unlikely to benefit shareholders IMO.
https://ih.advfn.com/stock-market/NASDAQ/synaptogenix-SNPX/stock-news/92442316/synaptogenix-acquires-significant-stake-in-cannaso
Of course it is and most DON'T know it. It's also beneficial when recruiting for these trials as well. Evidently the market thought it was important as well, even if most of those on this board knew it already.
It certainly differentiates it in the safety department from any approved drug. Not everyone understands the MOAs of each of the drugs but knowing its safe is important to most. Nice 50% bump of the bottom! Probably not going to be greedy here
Thats why I almost bought back in for a quick trade before the bounce back above 12. You have to figure more insider purchases on the way but price has to be lower than 12 for me. Jmho
Never been sure what to make out of the accusations from preclinical the work. Not sure why some have been so nervous about allowing the trials to move forward. Very fortunate it would seem that the trials are as far along as they are. I've been hesitant to tie money up as I figure they will eaise funds before results but I'll consider gambling if it dips under 10. Results being 15 months away doesn't help though.
Holy crap. Guess so
You don't know what it means because I think you may not understand how cheap some purchased this stock. Your post makes no since. Folks could have bought this hand over fist below 2 bucks. I didn't get quite that cheap. Quite that is and yes multiple times I have 20 bagged or more these stocks. It's all public record. I've also lost before too. I don't pretend to be a bio executive, nor accuse others to be something they are not.
Yeah he has led a bunch of folks astray that hung on there all the way down and he'll lose folks here money too if they don't trade the bumps imo
Nothing we don't already know but author did interview other experts in the field.
https://www.medicalnewstoday.com/articles/bryostatin-1-may-halt-cognitive-decline-in-advanced-alzheimers-disease-trial-finds
Sure. Only 20 bagged this one. Try again
You might be down some on another AD table pounder he's pumped for awhile.
Nothing changes the fact this is heading for a reverse split and is years away from any type of AD approval Imo. We don't even know when the next AD trial will kick off or what they could potentially squander the cash on this go around as they look for "strategic alternatives". That's the current fear
Not sure how meeting data time lines on OLE doesn't count but transparency has ruled the day as to the P3 trials enrollment and garnering the SPA from the FDA so the market will know what to expect. At least when results are released folks will have an idea what the FDA will think of them. Praying they will successful while not gambling the farm that they will be.
I never saw any predictions on your part (at least on this stock) but regardless they have put out nearly monthly enrollment numbers every step of the way updated with every PR and filing so investors would know, especially in light of the shorts doing everyting they could to stop the trial. SAVA has put out multiple PR updates on previous trial data and peer-reviewed that have always been met in a timely fashion. Now I'll wait on company trial guidance from the company while only trading the pullbacks and spikes if I do anything at all.
Not my strong point man. Wish I could be more helpful without reading through all the filings and PRs. GL
Yes before the short attack slowed things. They've been spot on ever since that played out. I told folks 2 years ago I expected enrollment complete by Oct 2023 and folks can check that record. They also can check Remis record with other trial data. When the company guides Q4 2023 or Q1 2024 I'll reassess then. I normally figure 2/3 months but maybe the holidays slow it or maybe it reads out just before.
I thought it was a 1 to 5 ratio for the Petros spinoff but you may want to check the 10k which should state it. My guess is if you had 1000 shares of Ntrp then you got 200 shares of petros which would be 20 shares after their split. Also the NTRP were split after that spinoff to gain Nasdaq but I don't remember what that split number was. 10k will tell. I'm just going on the fly
Keep in mind the Petros spinoff shares which I believe were originally at a 5 for 1 share dividend, have also been split by a 10th I believe.
You probably need to call your broker and tell them about the splits and the Petros spinoff and hopefully they could more easily figure it out. I would be hesitent to take a guess. Depending on when you bought here there have been 2 separate splits and the spinoff.
I'll wait for company guidance and trust that, whatever it may be. They've run an incredibly efficient trial for a company that has never un a larger P3. Must better than most I follow. Has no impact on whether the drug works or not of course but at least the market will trust whatever timeline is given for this one.
When people research how little time the patent has left, besides the poor sales, they will understand why the stock trades so low
Could be. I imagine they'll be much quicker than competitors
Originally I had figured Q4 next year so you could be close
The beat goes on. Glad its complete. Countdown clock becomes a little more accurate
It's interesting but they did do MRIs and the average time from initial diagnosis for this trial was over 3 years. I would like to see the patients screened from the diagnostic company you mentioned with the FDA approved diagnostic test that included PKCE monitoring.
Thanks for the link. Finally got to sit down at a desktop and read. Pages 5-7 are very in depth with individual patient scores plotted on the graphs. Separation at every data point and stat significant and growing from week 13 and beyond. Does lend some credence to the synaptic growth and maintenance MOA. Oddly enough one of the reasons the drug didn't prove stat significant over the more mild subgroup was once again due to the placebo group scoring a mean of +5 points. Definitely interesting data. I had previously had doubts as to whether an additional AD trial would be run, but it would be kind of hard to not run another one in a similar population after these results. Still the "n" is rather small and there are certainly questions lingering. That's the science. Now as an investment its currently trash and will likely be so until the inevitable reverse split or even longer IMO.
I want to know if there is data that shows a 12 point decrease in SIB at this stage of dementia (or any stage of severe AD) could be expected over 10 months or what the company expectations were for the placebo. Maybe Doc will chime in with any thoughts at some point. I realize the numbers in this group are likely fairly small
The peer review shows that the more severe patient placebo group declined over 12 points. I wonder how common that is in the AD population? We know that most of those patients were probably still taking other AD meds (other than memantine of course). It just seems like a big drop off and I'm trying to wrap my head around how memantine comes into play, if at all vs the odds that bryostatin stopped the decline cold for almost a year. Still thinking on this one.
Yes they have shares to sell for years as volume is just so bad routinely
Maybe NIH will fund another AD trial.
Glad they are presenting
That's 10 year old news Mac. All trials have super responders.
Easy to say but never demonstrated. Slowing decline is all that's been shown